Breakfast or not? new study tests Food's impact on brain drug

NCT ID NCT07292233

Ongoing Knowledge-focused Sponsor: Luye Pharma Group Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing how eating food changes the way the body absorbs a new experimental drug called LY03020. The drug is being developed for schizophrenia and psychosis related to Alzheimer's disease. Sixteen healthy volunteers will take the drug once with food and once without, so researchers can compare the levels in their blood and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY03020 (LPM787000048 maleate extended-release tablets)
What this could lead to: If successful, this study could help determine the best way to take LY03020 with or without food, guiding future trials for treating schizophrenia and Alzheimer's disease psychosis.
What could go wrong: This is a very early phase 1 trial in only 16 healthy people, not patients. It only measures how food affects drug levels, not whether the drug works for the intended conditions. The drug may still fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE PSYCHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE PSYCHOSIS SCHIZOPHRENIA

Contacts and locations

Locations

Beijing AnDing Hospital Capital Medical University

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.